

Novo Nordisk makes Wegovy available in Singapore for weight management

15 July 2025 | News

Once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity



A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.

Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥ 30 kg/m²), or who are overweight (BMI ≥ 27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.

The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake. This mechanism supports weight loss when combined with sustainable lifestyle changes.

The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity, a condition associated with more than 200 health complications. Despite its prevalence and medical complexity, obesity remains heavily stigmatised, often misunderstood as merely the result of poor personal choices.